FSTX 外匯新聞
F-star Therapeutics Inks License Deal With Takeda To Develop Bispecific Antibody
Biopharmaceutical company F-star Therapeutics, Inc. (FSTX), operating through its subsidiary, F-star Therapeutics Ltd., announced Wednesday that it has entered into a license agreement with Japan's Takeda Pharmaceutical Co. Ltd. (TAK) to develop a bispecific antibody.
RTTNews
|
1528天前
